Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Ponatinib Stories

2014-02-12 08:28:26

- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb. 12, 2014 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today positive pre-clinical results for BL-8040 in a third indication - as a treatment for chronic myeloid leukemia. Results of the study were recently published in Molecular Cancer Therapeutics. (Logo:...

2013-11-27 08:25:33

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, November 27, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Bristol-Myers Squibb Company (NYSE: BMY), Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Dyax Corp. (NASDAQ: DYAX), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), and Immunomedics Inc. (NASDAQ: IMMU). Today's readers may access these reports free of charge - including full price targets,...

2013-11-01 16:23:48

WHITE PLAINS, N.Y., Nov. 1, 2013 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) is aware of the FDA's decision requesting Ariad Pharmaceuticals to suspend marketing and sales of Iclusig (ponatinib), a therapy for chronic myeloid leukemia (CML). As suggested by the FDA, LLS encourages all patients currently receiving ponatinib to speak with their physician to discuss the risk and benefits of continuing treatment with the drug. Those patients who are responding well to...

2013-09-23 23:04:49

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022. London (PRWEB) September 23, 2013 PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United Kingdom Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia...

2013-09-19 08:28:21

- CML community recognizes September 22 as World CML Day to raise awareness of the needs of patients living with CML EAST HANOVER, N.J., Sept. 19, 2013 /PRNewswire/ -- Novartis commemorates World CML Day by announcing the latest milestone in its unique clinical trial program evaluating the potential for patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) to maintain undetectable levels of disease after stopping drug therapy - a concept called treatment-free...

2013-09-18 23:04:35

Reportbuyer.com just published a new market research report: PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022 London (PRWEB) September 18, 2013 Summary GlobalData has released its new Country report, “PharmaPoint: Chronic Myeloid Leukemia (CML) - United States Drug Forecast and Market Analysis to 2022”. Chronic myeloid leukemia (CML) is a rare myeloproliferative blood cancer that is characterized by the presence of the BCR-ABL...

2013-04-25 20:14:26

Increasing, unsustainable prices for leukemia drugs represent larger issue across all cancers The increasing cost of treatments for chronic myeloid leukemia (CML) in the United States has reached unsustainably high levels and may be leaving many patients under- or untreated because they cannot afford care, according to a Blood Forum article supported by nearly 120 CML experts from more than 15 countries on five continents and published online today in Blood, the Journal of the American...

2013-02-22 08:22:43

LONDON, February 22, 2013 /PRNewswire/ -- Biotech sector has a promising future. With the rise in occupational and lifestyle ailments, the demand for biotech products is expected to rise. Increased age expectancy is another major factor behind the growth of the sector. However, biotech companies work in an uncertain environment and the fortunes of a company may make or break with a single FDA decision. Ariad Pharmaceuticals Inc. (NASDAQ: ARIA) recently received approval for its...

2013-01-30 12:26:52

BURLINGTON, Mass., Jan. 30, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts the launch of new agents positioned for the treatment of both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) through 2018. According to two Niche Markets and Rare Diseases reports, Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, novel targeted therapies hold the most promise for...

Rare Leukemia Drug Receives FDA Approval
2012-12-16 06:40:58

redOrbit Staff & Wire Reports - Your Universe Online The US Food and Drug Administration (FDA) has approved a new drug for the treatment of two rare forms of leukemia, including chronic myeloid leukemia (CML), various media outlets have reported. Ponatinib, a third-generation, multi-targeted tyrosine kinase inhibitor that will be marketed by Ariad Pharmaceuticals under the brand-name Iclusig, received the go-ahead on Friday, some three months before the agency was required to act on...